Internal Medicine, Hematology & Oncology · Huntsville, AL
NPI
1457650848
Since 2011
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
3601 Cci Dr NW
Huntsville, AL, 35805
Phone (256) 705-4224
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.3M
204,575 services
Medicare patients, 2024
1,017
Average age 75
Drug cost, 2024
$6.0M
2,236 prescriptions
Company payments, 2025
$3,199
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel M Schreeder was code J9271 (injection, pembrolizumab, 1 mg), 19,000 times for 18 patients. In total Daniel M Schreeder billed 204,575 services in 208 codes, and Medicare paid $4.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-01-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 19,000 | 18 | $44.59 | $847K |
| J9299 Injection, nivolumab, 1 mg | Office | 13,080 | 14 | $24.53 | $321K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 11,700 | 18 | $39.64 | $464K |
| J9267 Injection, paclitaxel, 1 mg | Office | 10,637 | 12 | $0.08 | $849 |
| J0185 Injection, aprepitant, 1 mg | Office | 7,670 | 15 | $1.32 | $10K |
| J0897 Injection, denosumab, 1 mg | Office | 6,120 | 42 | $20.40 | $125K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 4,900 | 44 | $15.59 | $76K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,549 | 70 | $0.09 | $225 |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2,030 | 15 | $37.18 | $75K |
| 85025 Blood Count | Office | 1,952 | 809 | $7.56 | $15K |
| 36415 Venipuncture Blood Collection | Office | 1,938 | 793 | $8.64 | $17K |
| 80053 Clinical Chemistry | Office | 1,909 | 806 | $10.28 | $20K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,206 | 54 | $0.23 | $273 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 1,050 | 32 | $0.24 | $254 |
| 99214 Office E&M - Established | Office | 882 | 372 | $89.95 | $79K |
By year: 2022 $4.6M for 247,388 services; 2023 $3.7M for 177,362 services; 2024 $4.3M for 204,575 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,952 | 809 | $7.56 | $15K |
| 36415 Venipuncture Blood Collection | 1,938 | 793 | $8.64 | $17K |
| 80053 Clinical Chemistry | 1,909 | 806 | $10.28 | $20K |
| 88185 Surgical Pathology Examination | 753 | 37 | $15.74 | $12K |
| 82728 Clinical Chemistry | 387 | 287 | $13.10 | $5,068 |
| 83540 Clinical Chemistry | 386 | 285 | $6.21 | $2,399 |
| 83550 Clinical Chemistry | 383 | 283 | $8.40 | $3,217 |
| 82784 Immunoassay | 357 | 95 | $9.04 | $3,229 |
| 83883 Clinical Chemistry | 320 | 106 | $12.96 | $4,149 |
| 83735 Clinical Chemistry | 252 | 113 | $6.57 | $1,656 |
Medicare prescription drug claims, 2024
In 2024, the drug Daniel M Schreeder prescribed most often to Medicare patients was Anastrozole, with 229 prescriptions and refills. In total Daniel M Schreeder wrote 2,236 Medicare prescriptions that cost $6.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 229 | 582 | 68 | $6,086 |
| Eliquis Apixaban | 209 | 262 | 47 | $151K |
| Ondansetron Hcl Generic | 87 | 87 | 42 | $809 |
| Revlimid Lenalidomide | 76 | 76 | 11 | $1.3M |
| Xarelto Rivaroxaban | 65 | 87 | 12 | $45K |
| Valacyclovir Valacyclovir Hcl | 59 | 67 | 13 | $2,783 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 54 | 54 | 24 | $1,577 |
| Dexamethasone Generic | 52 | 63 | 15 | $665 |
| Xtandi Enzalutamide | 45 | 45 | Under 11 | $567K |
| Olanzapine Generic | 44 | 51 | 22 | $306 |
| Potassium Chloride Generic | 43 | 47 | 23 | $633 |
| Hydroxyurea Generic | 43 | 77 | Under 11 | $841 |
| Lenalidomide Generic | 42 | 42 | Under 11 | $565K |
| Trazimera Trastuzumab-Qyyp | 42 | 42 | Under 11 | $108K |
| Prednisone Generic | 41 | 43 | 12 | $174 |
Brand drugs: 741 claims; generic drugs: 1,495 claims; opioid claims: 144.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel M Schreeder $3,199 ($3,199 in general payments such as food, travel and fees) from 27 companies. The largest payer was Janssen Biotech, Inc. with $1,602.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 3 | $1,602 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $187 |
| Kite Pharma, Inc. GILD | 2 | $165 |
| Genzyme Corporation SNY | 2 | $157 |
| Genmab U.S., Inc. GMAB | 1 | $142 |
| GlaxoSmithKline, LLC. GSK | 1 | $112 |
| Daiichi Sankyo Inc. 4568.T | 5 | $107 |
| Pfizer Inc. PFE | 5 | $100 |
| BeOne Medicines USA, Inc. ONC | 5 | $91.01 |
| Celgene Corporation BMY | 3 | $70.85 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.